Registration Now Open: Karmanos and Wayne State University’s 3rd Annual Lung Cancer Symposium

Back to Results Print news article

Learn about the latest breakthroughs in thoracic oncology, knowledge that can be translated into everyday practice

The Barbara Ann Karmanos Cancer Institute and Wayne State University will host the Third Annual Lung Cancer Symposium, bringing together some of the nation’s most respected leaders in thoracic oncology for a day of leading-edge science, practical insights and collaborative discussion.

This year’s program features national experts in thoracic oncology research and treatment:

  • Elliott Brea, M.D., Ph.D. – Dana Farber Cancer Institute
  • Ryan Gentzler, M.D. – University of Virginia
  • Meera Patel, M.D. – Baylor College of Medicine
  • Saiama Waqar, M.D., MSCI – Washington University School of Medicine
  • Antoinette Wozniak, M.D. – Lung Cancer Research Foundation

In addition, Karmanos Cancer Institute’s clinical researchers and faculty will deliver insights into the latest in lung cancer treatment and discoveries. The symposium is led by Hirva Mamdani, M.D., symposium program director and leader of the Thoracic Oncology Multidisciplinary Team (MDT), and includes presentations by the following MDT members:

Program Highlights

Participants will gain first-hand knowledge on transformative advances across the lung cancer spectrum, including:
  • Innovative strategies in lung cancer screening and perioperative therapy for resectable non-small cell lung cancer (NSCLC).
  • Recent advances in small cell lung cancer that are redefining the standard of care for a disease long considered one of oncology’s greatest challenges.
  • Novel approaches for advanced NSCLC with epidermal growth factor receptor (EGFR) mutations without actionable genomic alterations.
  • The latest updates in targeted therapy for ALK, HER2, KRAS, MET, and ROS-1 alterations.
  • Integrating shared decision-making into personalized patient care.

Each topic will include case-based panel discussions, bridging the gap between rapidly evolving research and real-world patient care. Attendees will leave with actionable strategies to incorporate the newest evidence into their daily practice

"We are very excited for this year’s symposium. This event is a vital endeavor, as the field of thoracic oncology is evolving at an unprecedented speed, marked by a surge in FDA-approved treatment options and an ever-growing number of clinical trials,” said Dr. Mamdani, who is also a member of the Phase I Clinical Trials MDT and the Molecular Therapeutics Research Program at Karmanos, and an associate professor in the department of oncology at WSU’s School of Medicine. “The symposium provides an invaluable platform for experts to dissect and interpret the latest data, empowering clinicians to navigate the complexities of this expanding field and to make individualized treatment decisions for patients with lung cancer.”

Registration Details

This year’s symposium will be held at Detroit Marriott Troy. This activity has been approved up to 5.50 AMA PRA Category 1 Credit™.

Registration is required. The cost is $60 for physicians; $30 for retired physicians, pharmacists, mid-level providers, nurses, CTO staff and allied health providers; and $20 for fellows, residents and medical students, whose costs are refundable upon attendance. The deadline to register is Thursday, Sept. 25. Register online at karmanos.org/lung-cancer-symposium.

For additional information, contact Pamelia Sydorchuk, symposium coordinator, at symposium@karmanos.org or 313-576-8746.

To download the flyer, click here.

Join the discussion during the symposium on LinkedIn and Facebook by using #KarmanosLung.